THERADIAG secures a standby equity facility (SEF®) with Société Générale

  THERADIAG secures a standby equity facility (SEF®) with Société Générale

Business Wire

CROISSY-BEAUBOURG, France & MONTPELLIER, France -- April 16, 2014

Regulatory News:

Theradiag (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER), a company
specializing in theranostics and in vitro diagnostics, announces that it has
set up a standby equity facility (SEF®) with Société Générale, as approved by
shareholders at the Annual General Meeting of April 8, 2014.

“We have entered into an active phase for the commercial development of our
innovative products in France and internationally, and we want to insure that
we have the financial means to support our ambitions,” comments Michel
Finance, CEO of Theradiag. “This standby equity facility strengthens our
financial flexibility and diversifies our sources of financing, while
preserving our financial structure thanks to a limited discount. The funds
raised will notably allow us to strengthen the development of our theranostics
portfolio in the United States.”

At Theradiag’s request, Société Générale is committed to subscribe to
successive capital increases, issued by tranches over the next 24 months,
within the global limit of 445,000 shares, i.e. 9.9% of the number of shares
currently outstanding^1.

For each tranche, the issuance price will reflect the volume-weighted average
price of shares for the three trading days immediately preceding the issue
date, minus a discount of nomorethan 5%. This discount will enable Société
Générale to instantly underwrite the shares despite possible market
volatility. Acting as financial intermediary, Société Générale has no
intention to remain a shareholder of the Company.

Should the entire standby equity facilty be drawn^2, a shareholder currently
owning 1.0% of the company’s share capital would see his or her share
ownership reduced to 0.91%^3.

About Theradiag

Capitalizing on its expertise in the distribution, development and
manufacturing of in vitro diagnostic tests, Theradiag innovates and develops
theranostics tests (combining treatment and diagnosis) that measure the
efficiency of biotherapies in the treatment of autoimmune diseases, cancer and
AIDS. Theradiag notably markets the Lisa-Tracker range (CE marked), which is a
comprehensive multiparameter theranostic solution for patients with autoimmune
diseases treated with biotherapies. With its subsidiary Prestizia, Theradiag
is developing new biomarkers based on microRNAs for the diagnosis and
monitoring of HIV/AIDS and rectal cancer. Theradiag is thus participating in
the development of “customized treatment”, which favors the individualization
of treatments, the evaluation of their efficacy and the prevention of drug
resistance. The Company is based in Marne-la-Vallée, near Paris, and in
Montpellier, and has over 60 employees.

For more information about Theradiag, please visit our website:
www.theradiag.com

^1 4,473,150 shares currently outstanding
^2 Leading to the issuance of 445,000 new shares
^3 Based on the non-fully diluted number of shares currently outstanding

Contact:

Theradiag
Investor Relations
Nathalie Trepo, +33 1 64 62 10 12
ntrepo@theradiag.com
or
NewCap.
Financial communications/ investor relations
Valentine Brouchot / Pierre Laurent, +33 1 44 71 94 94
theradiag@newcap.fr
or
Alize RP
Press
Caroline Carmagnol, +33 6 64 18 99 59
theradiag@alizerp.com
 
Press spacebar to pause and continue. Press esc to stop.